Drivers and trajectories of resistance to new first-line drug regimens for tuberculosis.

ABSTRACT:

Background

New first-line drug regimens for treatment of tuberculosis (TB) are in clinical trials: emergence of resistance is a key concern. Because population-level data on resistance cannot be collected in advance, epidemiological models are important tools for understanding the drivers and dynamics of resistance before novel drug regimens are launched.

Methods

We developed a transmission model of TB after launch of a new drug regimen, defining drug-resistant TB (DR-TB) as resistance to the new regimen. The model is characterized by (1) the probability of acquiring resistance during treatment, (2) the transmission fitness of DR-TB relative to drug-susceptible TB (DS-TB), and (3) the probability of treatment success for DR-TB versus DS-TB. We evaluate the effect of each fac

SUBMITTER: Shrestha S 

PROVIDER: S-EPMC4281792 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature